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Abstract
Screening chemical libraries to identify compounds that affect overall cell proliferation is common. However, in most cases,
it is not known whether the compounds tested alter the timing of particular cell cycle transitions. Here, we evaluated an
FDA-approved drug library to identify pharmaceuticals that alter cell cycle progression in yeast, using DNA content
measurements by flow cytometry. This approach revealed strong cell cycle effects of several commonly used
pharmaceuticals. We show that the antilipemic gemfibrozil delays initiation of DNA replication, while cells treated with
the antidepressant fluoxetine severely delay progression through mitosis. Based on their effects on cell cycle progression,
we also examined cell proliferation in the presence of both compounds. We discovered a strong suppressive interaction
between gemfibrozil and fluoxetine. Combinations of interest among diverse pharmaceuticals are difficult to identify, due
to the daunting number of possible combinations that must be evaluated. The novel interaction between gemfibrozil and
fluoxetine suggests that identifying and combining drugs that show cell cycle effects might streamline identification of drug
combinations with a pronounced impact on cell proliferation.
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Introduction
Adjusting rates of cell proliferation is the objective of many
therapeutic strategies. Most often, the goal is to impede or block
cell proliferation of target cells, as with chemotherapy in cancer. In
other cases, as in tissue regeneration, the goal is to promote cell
proliferation. Proliferating eukaryotic cells pass through a series of
highly regulated cell cycle phases, culminating with mitosis [1].
Hence, drugs that influence the timing of cell cycle transitions are
useful in efforts to adjust rates of cell proliferation.
Identifying drugs that potentiate the effects of other drugs is the
leading therapeutic strategy in the treatment of numerous diseases,
such as cancer [2], tuberculosis [3] and HIV-AIDS [4].
Conversely, drug interactions may suppress a desired response,
or even lead to a harmful outcome. Screening libraries composed
of a few hundred thousand compounds for a sought-after effect of
a single chemical is now common [5]. However, testing all the
possible combinations, even binary ones, of these chemicals
represents a formidable obstacle [6].
Here we report a systematic analysis of cell cycle progression of
yeast cells exposed to a panel of FDA-approved drugs. We
document novel cell cycle effects of several compounds. We also
reasoned that drugs that affect cell cycle progression might be
more likely to display interactions with other such drugs, and
thereby greatly impact overall cell proliferation. We demonstrate
one such novel drug interaction, between gemfibrozil and
fluoxetine.
Results and Discussion
We used a commercially available panel of 640 FDA-approved
drugs (see Materials and Methods). The target cells were
Saccharomyces cerevisiae budding yeast, a model system of eukaryotic
cell cycle studies [1]. We monitored the effects of each drug on cell
cycle progression by measuring the DNA content of the cells by
flow cytometry [7] (see Figure 1, and Materials and Methods). The
G1 phase of any given cell cycle lasts from the end of the previous
mitosis (M phase) until the beginning of DNA synthesis (S phase).
Any drug that alters the length of the G1 phase relative to the rest
of the phases of the cell cycle will alter the DNA content profile.
We quantified each sample in an automated manner, recording
the percentage of cells with unreplicated genome (%G1, see
Materials and Methods). We did not quantify complex profiles (see
Figure 2), and we excluded these drugs from further analyses. At
the beginning and end of most batches of samples, we measured
the reference sample (a yeast strain that lacks the multidrug
transporters Pdr5p and Snq2p, mock-treated with DMSO; see
Materials and Methods), which was cultured and processed along
with the cultures that were treated with drugs. We evaluated each
drug in at least two independent experiments. We deposited all
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Figure 1. Decision flow-chart diagram of our primary analysis. This diagram summarizes our DNA content measurements using the pdr5D,
snq2D strain. See text for details.
doi:10.1371/journal.pone.0036503.g001
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Figure 2. Representative DNA content histograms. Independent experiments of the indicated samples are shown in each case. Fluorescence is
plotted on the x-axis, while the number of cells analyzed is on the y-axis. Reference samples were treated with DMSO, shown at the top. Examples of
‘‘High G1’’ profiles include cells treated with ketoconazole or gemfibrozil, while cells treated with fluoxetine give rise to a ‘‘Low G1’’ DNA content
profile. At the bottom, we show a few examples of complex DNA content histograms that were unquantifiable. These include profiles of cells treated
with suramin and 5-fluorouracil (antineoplastic agents), and flubendazole (a microtubule blocker used as anti-nematodal).
doi:10.1371/journal.pone.0036503.g002
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raw flow cytometry data in a public database (see Dataset S1, and
Materials and Methods).
To identify drugs that altered the cell cycle, we compared the
frequency distribution of cultures treated with drugs against a
normal distribution fit of the reference (n = 82) samples (Figure 3A).
Samples that had a %G1 greater or less than two standard
deviations from the mean of the reference sample distribution were
considered to differ significantly from the mock-treated samples
(Figures 1 and 3A). Drugs that led to an increase (%G1.60.00%)
in the percentage of cells with unreplicated DNA formed the
‘‘High G1’’ group, while others led to a mitotic delay and a ‘‘Low
G1’’ (%G1,38.76) DNA content (see Figure 3A, and Dataset S1).
In this initial screen, we added the drugs to cultures diluted from
an overnight stationary phase culture, where most cells would be
in the G1 phase of the cell cycle [1]. Hence, drugs in samples with
a ‘‘High G1’’ DNA content may have arrested cell cycle
progression non-specifically. In that case, the high G1 DNA
content reflected the state of the starting culture, and not cell cycle
effects of the drugs. To exclude such possibilities, we re-tested the
‘‘High G1’’ drugs by adding them to actively dividing cells (see
Figure 1). Overall, from this primary analysis we identified 27
compounds that interfered with progression in the G1 phase of the
cell cycle, before initiation of DNA replication, resulting in a
‘‘High G1’’ DNA content (see Table S1). Another 12 drugs
affected mitotic progression, resulting in a ‘‘Low G1’’ DNA
content (see Table S2).
Along with DNA content, we also analyzed the forward scatter
(FSC) from the same flow cytometry experiments (see Figure 3B).
FSC values often serve as a proxy for cell size, but they are also
affected by cell shape and intracellular composition [8]. We
noticed that most drugs in the ‘‘Low G1’’ group had elevated FSC
values compared to the group with no cell cycle effects (Figure 3B).
This is consistent with the notion that mitotic delay leads to an
increase of cell size. It should also be noted that yeast cells in
mitotic phases of the cell cycle are budded [1]. Hence, their
irregular shape may also contribute to an increase in FSC values.
An increase of FSC values was also evident for a significant
fraction, but not all, of drugs in the ‘‘High G1’’ group (Figure 3B).
We are not aware of other systematic studies of drug effects on
cell cycle progression measured by DNA content analyses. Our
results reveal that several drugs currently and commonly used for
human therapy have specific effects on the eukaryotic cell cycle.
The higher number of drugs that interfered with G1 progression
likely reflects the fact that cells commit to initiation of cell division
in the G1 phase [1,9,10]. Among the ‘‘High G1’’ group, we noted
antifungals that inhibit biosynthesis of ergosterol, a component of
fungal membranes [11], and rapamycin, a potent inhibitor of the
TOR pathway known to block G1 progression [12]. Overall,
however, there was a diverse range of compounds in the ‘‘High
G1’’ group (see Table S1). Although most drugs in the ‘‘Low G1’’
group have well established mitotic roles (see Table S2), we noted
that the highest-ranked drug from this group was fluoxetine (brand
name Prozac). To our knowledge, this is the first time that such
strong cell cycle effects have been reported for fluoxetine.
Since we did our primary analysis in a sensitized pdr5D, snq2D
yeast strain, we then tested the drugs that led to the ‘‘High G1’’
and ‘‘Low G1’’ groups against the PDR5+, SNQ2+ wild type
reference strain BY4741. We found that several drugs were not
effective in this case. For example, lovastatin, which leads to a G1
arrest in mammalian cells [13], had no effect in PDR5+, SNQ2+
yeast cells (see Table S1). This is consistent with an earlier report
that yeast cells are sensitive to lovastatin in a pdr5D -dependent
manner [14]. Nonetheless, about half of the drugs in both groups
remained effective in cells with intact multidrug transporters (see
Tables S1 and S2).
Among drugs that led to a ‘‘High G1’’ DNA content, we further
examined the cell cycle effects of the potent antilipemic
gemfibrozil [15], a Peroxisome Proliferator-Activated Receptor a
(PPARa) agonist. To our knowledge, a G1 cell cycle role for
gemfibrozil has not been reported, in any system. The High G1
DNA content could result from roles specific to G1 progression, or
manifest in G1 as a ‘‘carryover’’ from roles in other cell cycle
phases. To distinguish between these two possibilities, we added
gemfibrozil to highly synchronous newborn G1 cells, obtained by
centrifugal elutriation [16,17].
As a function of time, we then measured cell size and the
percentage of budded cells (budding correlates with initiation of
DNA replication in yeast [1]). This allowed us to measure the
Figure 3. DNA content analysis identifies drug effects on cell
cycle progression. A, Cumulative histogram displaying the percent-
age of cells in the G1 phase of the cell cycle (%G1), for cells treated with
a panel of FDA-approved drugs. The bin width of the histogram is 1%,
with each bin containing all the drugs with values within the bin
boundaries. The black line superimposed to this histogram is the
normal distribution fit of the %G1 values of the reference sample. Bins
with values .2 sd from the mean of the wild type distribution are in
grey (‘‘Low G1’’ group) and black (‘‘High G1’’ group). B, From all the
samples we analyzed by flow cytometry, the %G1 is on the x-axis, and
the forward angle scattering (FSC) values on the y-axis. We colored the
data points of the sub-groups as in A.
doi:10.1371/journal.pone.0036503.g003
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length of the G1 phase accurately, by calculating two parameters:
i) the ‘‘critical size’’ these newborn daughter cells must attain to
initiate cell division; ii) the rate (‘‘growth rate’’) at which they grow
to their critical size. DMSO-treated cells had a critical size of
63.262.4 fl and a specific growth rate constant
k=0.32860.008 h21 (Figure 4). Rapamycin markedly prolonged
the G1 phase, because cells had to reach a substantially larger
critical size (79.461.2 fl) before they could initiate DNA
replication (Figure 4A). Rapamycin-treated cells also grew very
slowly (k=0.10460.004 h21, Figure 4B), although this effect was
evident ,1 h after addition of the drug (Figure S1). We found that
cells treated with gemfibrozil delayed initiation of DNA replica-
tion, not because they had altered critical size (65.460.6 fl,
Figure 4A), but because they reached that size slower than cells
treated with DMSO did (k=0.28760.07 h21, P=0.005,
Figure 4B). In addition, from the cell size distributions of
asynchronously dividing cells, we obtained the ‘‘birth size’’ of
newborn cells (see Materials and Methods). While DMSO-treated
cells had a ‘‘birth size’’ of 40.362.7 fl under these growth
conditions, gemfibrozil-treated newborn cells were significantly
smaller (30.164.7 fl, P=0.04, Figure 4C). Taken together, these
data show that the smaller ‘‘birth size’’ and slower ‘‘growth rate’’
of cells treated with gemfibrozil lengthen the G1 phase.
Next, we focused on the effects of gemfibrozil and fluoxetine on
overall cell proliferation rates. We tested these drugs alone and in
combination, at several doses (Figure 5A). We found that
gemfibrozil did not significantly affect overall cell proliferation at
the doses tested (Figure 5). Hence, the prolongation of the G1
phase by gemfibrozil is likely accompanied by compensatory
shortening of subsequent cell cycle phases, resulting in similar
overall generation time. On the other hand, fluoxetine arrested
proliferation of yeast cells at 200 mM (Figure 5A, first green bar to
the left; and Table S3, bottom left cell). To our knowledge, the
near complete inhibition of yeast cell proliferation by fluoxetine
has not been reported. Remarkably, however, addition of
gemfibrozil even at a 4-fold less molar concentration fully
suppressed the inhibitory effects of fluoxetine (see Figure 5A,
compare the left green bar to the other green bars; and Table S3,
last row).
We then added the two drugs not simultaneously, but in
different order, removing the first drug before adding the second
(Figure 5B). We found that gemfibrozil suppressed fluoxetine’s
anti-proliferative effects only if added before (representative
experiment in Figure 5B, compare the blue and yellow bars on
the right; and Table S4, compare the top and middle cells in the
3rd column), but not after fluoxetine (Figure 5B, compare the left
and middle green bars; and Table S4, compare the left and middle
cells in the 3rd row). These results suggest that the suppressive
interaction between gemfibrozil and fluoxetine is not due to
extracellular interaction or competition for transport between the
two drugs. Furthermore, the results from the order-of addition
experiment suggest that gemfibrozil acts upstream, since it does
not reverse fluoxetine’s inhibition of cell proliferation. Instead, it
appears that fluoxetine cannot inhibit cell proliferation in the
context of gemfibrozil’s prior action.
Understanding the basis of the interaction between gemfibrozil
and fluoxetine requires a mechanistic understanding of their
function in yeast cells. We examined the combined effects on cell
proliferation between gemfibrozil and fluoxetine because of the
novel cell cycle effects of each compound, affecting different
phases of the cell cycle. We would like to note, however, that the
suppressive interaction between the two compounds could be
unrelated to their cell cycle effects. For example, gemfibrozil might
induce expression of proteins that do not interfere with cell cycle
progression, but may cause fluoxetine resistance. Fluoxetine is an
anti-depressant thought to act as a serotonin-specific reuptake
inhibitor [18]. Hence, the effects we described for fluoxetine in
yeast appear to result from some other mechanism. Similarly,
nuclear receptors of the PPARa/RXR type, the target of
gemfibrozil, are thought to be unique to animals and sponges
[19,20], but ancestral analogs may exist in yeast [21]. Nonetheless,
although the effects of fluoxetine and gemfibrozil on yeast cells we
described above likely represent off-target modes of action, they
may act similarly in other eukaryotic organisms, including
humans. In conclusion, our results suggest that monitoring the
effects of drugs on cell cycle progression reveals unexpected
cellular roles of widely prescribed compounds. Finally, although
we did not test all possible combinations of the compounds that
affected cell cycle progression, at least in the case of gemfibrozil
and fluoxetine, our results suggest that combining such com-
pounds may also be an effective strategy to identify novel drug
interactions.
Materials and Methods
Yeast strains
For our primary analysis, we used the S. cerevisiae strain JTY2953
(MATa pdr5::TRP1 snq2::hisG ade2-101 his3-D200 leu2-D1 lys2-
801am trp1-D63 ura3–52; a generous gift from Dr. Paul deFigueir-
edo, Texas A&M University). For the elutriation experiments in
Figure 4 we used the diploid strain BY4743 (MATa/a his3D1/
his3D1 leu2D0/leu2D0 lys2D0/LYS2 MET15/met15D0 ura3D0/
ura3D0; commercially available from Open Biosystems). For all
other experiments, we used the haploid strain BY4741 (MATa
his3D1 leu2D0 met15D0 ura3D0; commercially available from Open
Biosystems).
Media and culture conditions
In all experiments, strains were cultured at 30uC in YPD (1%
yeast extract, 2% peptone, 2% dextrose). For our primary analysis
with the JTY2953 strain, overnight cultures were diluted 1:200
and aliquoted into 96-well plates, 198 ml per well. To each well we
then added 2 ml of a drug stock solution (2 mg/ml in DMSO),
resulting in a final drug concentration of 20 mg/ml. At the four
corner wells of each 96-well plate, the cultures were treated with
DMSO only. These cultures served as the mock-treated reference
samples. The plates were then placed at 30uC and incubated for
6–7 h. Each of the 200 ml cultures were then transferred to
microcentrifuge tubes containing 500 ml ethanol, and sonicated for
5 s. For the experiments where the drugs were added in dividing
JTY2953 cells, the overnight cultures were diluted 1:400 and
incubated for 3 h at 30uC. We then added the drugs of interest
and incubated the plates at 30uC for another 6 h before fixing the
samples in ethanol. For DNA content measurements in BY4741
cells, which proliferate faster than JTY2953 cells do, overnight
cultures were diluted 1:400, cultured for 2.16 h before we added
the drugs of interest, and then cultured for another 4.33 h before
they were fixed in ethanol.
Cell size determinations
To obtain size distributions from asynchronous cultures,
overnight cultures of BY4743 cells were diluted 1:500 in fresh
medium, and incubated for 2 h at 30uC. We then added the drugs
of interest and incubated at 30uC for another 4 h. Cell size was
then measured with a Beckman Z2 Channelyzer. For each sample
we analyzed, we obtained size distributions from two different
dilutions of cells. The average of the geometric mean of each size
DNA Content Analysis and Drug Interactions
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distribution was recorded. We used the Accucomp Beckman
software package to obtain the statistics of each size distribution.
Measurements of critical size and growth rate from
elutriated cultures
For isolation of early G1 daughter cells, cultures were grown in
YPD at 30uC to a density of,1–56107 cells/ml, then fractionated
with a Beckman JE-5.0 elutriator as described previously [16].
Early fractions containing predominantly (.95%) small unbudded
cells were collected by centrifugation, re-suspended in fresh
medium and aliquoted in three separate flasks. To each flask, we
then added as indicated rapamycin (at 0.1 mg/ml), gemfibrozil (at
50 mg/ml), or DMSO alone. After testing several doses of each
drug and measuring the DNA content, we decided to use these
concentrations because they were the lowest ones that resulted in
consistently pronounced effects in this strain background. The
cultures were incubated at 30uC. Every 20 min we monitored the
percentage of budded cells and cell size. The ‘‘critical size’’ is the
size at which 50% of the cells have budded in these experiments,
and it was calculated as we described elsewhere [16]. To calculate
‘‘growth rate’’ assuming exponential growth, we plotted the
natural log (ln) of cell size as a function of time (in h), see Figure
S1. We fit the data to a straight line using the regression function
in Microsoft Excel. From the slope of the line, we obtained the
specific rate of cell size increase constant (k, in h21). The average
of all experiments (n = 3) for each treatment was then calculated,
along with the associated standard deviation.
Staining for DNA content analyses
Fixed cells were stored at 4uC overnight to 14 days. Cells were
collected by centrifugation and stained overnight in 0.5 ml
staining solution containing 50 mM sodium citrate pH 7.0,
Figure 4. Gemfibrozil delays initiation of DNA replication. A, The critical cell size (shown in fl) of diploid BY4743 cells treated with DMSO,
rapamycin (0.1 mg/ml) or gemfibrozil (50 mg/ml), was measured from synchronous elutriated cultures, in YPD medium. The data points shown were
from three independent experiments in each case. The P values shown were calculated from paired, two-tailed t tests, assuming unequal variance.
The data used to calculate these parameters are shown in Figure S1. B, The specific rate of cell size increase constant k (in h21) was measured from
the same elutriation experiments shown in a, assuming exponential growth. The data used to calculate these parameters are shown in Figure S1. C,
The cell size distributions of the indicated cell populations, proliferating asynchronously in YPD medium, were measured using a channelyzer (see
Materials and Methods, and [22]). Cell numbers are plotted on the y-axis and cell size (in fl) on the x-axis. Daughter ‘‘birth’’ size was defined as the
maximum size of the smallest 10% of cells on the left side of the cell size distribution of each sample [22].
doi:10.1371/journal.pone.0036503.g004
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0.25 mg/ml RNaseA, and 1 mM SYTOX Green (Molecular
Probes). Samples were stored at 4uC overnight in opaque
containers. Cell suspensions were sonicated briefly at the fixing
and staining steps and immediately before flow cytometry.
Flow cytometry data acquisition, deposition and analysis
Stained cells were analyzed on a FACSCalibur (Becton
Dickinson Immunocytometry Systems) flow cytometer, using
CellQuest (version 3.3; Becton Dickinson Immunocytometry
Systems) acquisition software. Sytox Green fluorescence was
collected through a 515/30-nm bandpass filter, and list mode
data were acquired for 10,000 cells defined by a dot plot of FSC
versus SSC. Prior to each experiment, standard beads (Cyto-Cal
Multifluor Intensity Beads, Thermo Scientific) were used to
calibrate the flow cytometer, and photomultiplier tube voltages
were adjusted to place the highest intensity bead in the same
channel (+/2 3). FACS files were archived at Cytobank. Automated
quantification of the DNA content histograms was done with
FlowJo 7.5 software. To exclude particulate non-yeast events,
which had both very low forward scatter (FSC) and low
fluorescence (FL2-A), asymmetrical gates were fitted with the
autogating tool. Gates were centered near FSC ,100 and FL2-A
Figure 5. A novel interaction between gemfibrozil and fluoxetine. A, Fluoxetine strongly inhibits yeast cell proliferation, but it is suppressed
by gemfibrozil. We added to freshly reseeded wild type haploid yeast (BY4741) cells DMSO, fluoxetine and gemfibrozil at the binary combinations
and concentrations shown. We then monitored cell proliferation hourly, for 8 h (see Materials and Methods). The specific growth rate constant (k) for
each combination is shown. The errors associated with these measurements are shown in Table S2. B, DMSO, fluoxetine and gemfibrozil were added
to dividing cells at 200 mM in binary combinations, sequentially, in the order shown. Cell proliferation was monitored for 6 h as in a, with the specific
growth rate constant (k) for each combination shown. Data from one representative experiment is shown. Suppressive effects of gemfibrozil on
fluoxetine arising from order of addition were assessed by calculating growth rate constant (k) folds for gemfibrozil treatment over DMSO control for
all experiments, initial treatment with gemfibrozil yielding a fold of 2.51 +/2 0.25, versus final treatment, 0.71 +/2 0.21, P-value= 0.000146.
doi:10.1371/journal.pone.0036503.g005
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,300 and contained all events of sufficient contiguity as defined
by the default autogating parameters, on average ,95% of total.
From the gated populations, we determined the mean and
standard deviation of the FSC parameter. Cell cycle phase
subpopulations were computed from the gated population using
the Dean-Jett-Fox model without constraints. %G1 was defined as
the area of the G1 model peak, divided by the combined areas of
the G1 and G2/M peaks. Because the %G1 and associated
parameters represent continua across experiments, it was neces-
sary to identify model fits that did not accurately represent
experimental data. This was assessed primarily by root mean
square (RMS) error and ratio of mean fluorescence intensities
(MFI, calculated from the FL2-A parameter) of the G2/M vs. G1
peaks. Automated unconstrained analyses that yielded extremes in
these parameters, or extremes in %G1 or S-phase components of
the model fit, were manually constrained by application of the
median G2/G1 MFI ratio and a G1 MFI position that minimized
the resulting overall RMS. All model fits were visually inspected in
order to confirm the accuracy of the fit. Unquantifiable data was
excluded from further analysis. Experimental data and correla-
tions are provided in the searchable spreadsheet available as
Dataset S1. Raw data files can be freely accessed at Cytobank
(www.cytobank.org) and are found in the public experiments
‘‘Yeast DNA Content Project - DRUG - INCLUDED’’ and
‘‘Yeast DNA Content Project - DRUG -EXCLUDED’’.
Proliferation assays
Yeast strain BY4741 was grown overnight at 30uC in a 1 ml
YPD starter culture, then diluted 1:200 into fresh YPD in the
presence or absence of drug. 200 ml volumes were aliquoted into
clear flat-bottom 96-well sterile cell culture plates (Thermo
Scientific, Nunc MicroWell Plate 167008), and the absorbance
at 600 nm was measured hourly using a Tecan infinite 200Pro
plate reader, after one minute of 3.5 mm orbital shaking to re-
suspend cells. Plates were incubated standing at 30uC in between
measurements. Absorbances were blanked post-measurement
against wells containing media and DMSO alone. For combina-
tion assays, cells were treated with drug at the time of initial
reseeding, at a final DMSO concentration of 1.24% throughout,
aliquoted immediately into 96-well plates for reading of absor-
bance, and followed as described above. Growth constants were
calculated using a best fit for exponential growth incorporating
time points from 2 h through 6 h. For order of addition
experiments, cells were reseeded at 1:200 into fresh YPD in a
culture tube, cultured standing at 30uC with hourly re-suspension
for 3 h, then divided into three tubes and treated with the first
drug (200 mM) or DMSO-only control, at a final DMSO
concentration of 0.62% throughout. Following an additional 3 h
of incubation at 30uC, the primary treated cultures were washed
twice with fresh YPD at 30uC, re-suspended in the same, and
further divided for treatment with the second drug, as above,
resulting in nine total temporal combinations of vehicle, gemfi-
brozil, and fluoxetine. Growth constants were calculated as above
from 0 h through 6 h.
Drugs
The FDA-approved library was purchased from Enzo (Cat. #:
BML-2841). Artemisinin was from Enzo (Cat. #: ALX-350-219),
gemfibrozil from Sigma (Cat. #: G9518), while chlorpromazine
(Cat. #: 101077-482), fluoxetine (Cat. #: 89160-860) and
clinafloxacin (Cat. #: 89150-368) were purchased through VWR
International. All drug stock solutions were in DMSO.
Supporting Information
Figure S1 Determining the length of G1. Left, Graphs from
which we determined the specific rate of cell size increase constant
k, shown in Figure 4, from the same elutriation experiments. The
natural log cell size (y-axis) is plotted against time (shown in hours,
x-axis). Right, Graphs of the fraction of budded cells (y-axis) as a
function of cell size (in fl, x-axis), from the same elutriation
experiments. The data points shown were used to estimate the
critical size for division we show in Figure 4A. In A, the cells were
treated with DMSO, in B with rapamycin (at 0.1 mg/ml), and in C
with gemfibrozil (at 50 mg/ml).
(TIF)
Table S1 Drugs that lead to a High G1 DNA content.
(DOCX)
Table S2 Drugs that lead to a Low G1 DNA content.
(DOCX)
Table S3 Fluoxetine strongly inhibits yeast cell prolif-
eration, but it is suppressed by gemfibrozil.
(DOCX)
Table S4 Gemfibrozil suppresses fluoxetine’s anti-pro-
liferative effects only if added before, but not after,
fluoxetine.
(DOCX)
Dataset S1 Searchable spreadsheet of all the primary
data, arranged in different worksheets.
(XLSX)
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